<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Assessment for weight-related comorbidities in children and adolescents with obesity&lt;sup&gt;[1-5]&lt;/sup&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Assessment for weight-related comorbidities in children and adolescents with obesity<sup>[1-5]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Assessment for weight-related comorbidities in children and adolescents with obesity<sup>[1-5]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="20%"></colgroup><colgroup span="2" width="30%"></colgroup> <tbody> <tr> <td class="subtitle1">Condition</td> <td class="subtitle1">Clinical presentation/examination</td> <td class="subtitle1">Tests</td> <td class="subtitle1">Notes</td> </tr> <tr> <td>Dyslipidemia</td> <td>Asymptomatic or family history of CVD</td> <td><strong>Screening test:</strong> <ul class="decimal_heading"> <li>Fasting lipid profile</li> </ul> <p class="extra_spacing_top"><strong>Timing:</strong></p> <ul class="decimal_heading"> <li>Screen at age ≥10 years for all children with overweight or obesity<sup>[3]</sup></li> <li>Evaluate earlier for selected children with multiple risk factors</li> </ul> </td> <td> <ul> <li>Additional risk factors include family history of CVD, other obesity comorbidities (hypertension, diabetes), or tobacco use</li> <li>Refer to UpToDate content on dyslipidemia in children for interpretation and follow-up</li> </ul> </td> </tr> <tr class="highlight_lght_gray_text"> <td rowspan="2">Hypertension</td> <td rowspan="2">Asymptomatic; detected on routine monitoring</td> <td><strong>Screening test:</strong> <ul class="decimal_heading"> <li>BP measurement</li> </ul> <p class="extra_spacing_top"><strong>Timing:</strong></p> <ul class="decimal_heading"> <li>Measure at all health care visits (and at least annually)</li> </ul> </td> <td> <ul> <li>Use appropriately sized cuffs and age-appropriate norms</li> <li>Multiple measurements are required to diagnose or exclude hypertension</li> </ul> </td> </tr> <tr class="highlight_lght_gray_text"> <td><strong>Follow-up tests:</strong> <ul class="decimal_heading"> <li>24-hour ABPM</li> <li>CBC, metabolic panel, renin assay, urinalysis, kidney ultrasound</li> </ul> </td> <td> <ul> <li>ABPM is used to evaluate for "masked" hypertension; rule out "white coat" hypertension</li> <li>ABPM is suggested if the diagnosis is unclear from random office BP measurements</li> <li>Blood tests are suggested if hypertension is confirmed to exclude other causes of hypertension</li> </ul> </td> </tr> <tr> <td rowspan="2">Metabolic dysfunction-associated steatotic liver disease (MASLD; formerly termed nonalcoholic fatty liver disease)</td> <td rowspan="2">Generally asymptomatic; may have RUQ tenderness or hepatomegaly</td> <td><strong>Screening test:</strong> <ul class="decimal_heading"> <li>Serum ALT</li> </ul> <p class="extra_spacing_top"><strong>Timing:</strong></p> <ul class="decimal_heading"> <li>Initiate screening with serum ALT for all children with obesity starting at ≥10 years</li> </ul> </td> <td> <ul> <li>If ALT is normal, repeat at least every 2 to 3 years<sup>*</sup></li> <li>Diagnosis also depends on cardiometabolic risk factors (lipids and HbA1c or fasting glucose)</li> </ul> </td> </tr> <tr> <td><strong>Follow-up tests:</strong> <ul class="decimal_heading"> <li>Abdominal ultrasound to evaluate for anatomical abnormalities</li> <li>Laboratory tests for cardiometabolic risk factors<sup>¶</sup>; evaluation for viral hepatitis, autoimmune hepatitis, and endocrine disorders</li> <li>Exclude genetic disorders in selected patients</li> <li>Liver biopsy</li> </ul> </td> <td> <ul> <li>Perform these follow-up tests if ALT is &gt;80 units/L, persistently elevated &gt;2 times the ULN<sup>*</sup> for 6 months, or other signs/symptoms of advanced liver disease are present</li> <li>The purpose of follow-up tests is to determine the cause of elevated transaminases</li> <li>Liver biopsy may be helpful in some cases, such as when diagnosis is uncertain or there is concern for severe progression</li> <li>A definitive diagnosis of MASH can only be made by liver biopsy, but this is not always necessary for clinical management (refer to UpToDate content on MASLD)</li> </ul> </td> </tr> <tr class="highlight_lght_gray_text"> <td>Gallbladder disease</td> <td>Recurrent RUQ abdominal pain, sometimes with fatty food intolerance, nausea, vomiting, or jaundice</td> <td> <ul> <li>Abdominal ultrasound</li> <li>AST, ALT, GGTP, total bilirubin</li> <li>Amylase, lipase</li> </ul> </td> <td> <ul> <li>Complications may include acute pancreatitis or cholangitis</li> </ul> </td> </tr> <tr> <td>Type 2 diabetes mellitus or impaired glucose tolerance</td> <td>Often asymptomatic; may present with urinary frequency, nocturia, polydipsia, or polyuria</td> <td><strong>Screening test:</strong> <ul class="decimal_heading"> <li>Fasting glucose, HbA1c, or oral glucose tolerance test</li> </ul> <p class="extra_spacing_top"><strong>Indications:</strong></p> <ul class="decimal_heading"> <li>Perform in children ≥10 years old with overweight or obesity <strong>and</strong> 1 or more risk factors for type 2 diabetes<sup>Δ</sup></li> </ul> </td> <td> <ul> <li>Diabetes is diagnosed if fasting glucose ≥126 mg/dL or HbA1c ≥6.5% on 2 occasions</li> <li>Prediabetes is diagnosed if fasting glucose 100 to 125 mg/dL or HbA1c 5.7 to 6.4% on 2 occasions</li> </ul> </td> </tr> <tr class="highlight_lght_gray_text"> <td>Sleep apnea</td> <td>Habitual snoring, mouth breathing, daytime sleepiness, or inattentive behaviors and/or adenotonsillar hypertrophy</td> <td><strong>Screening:</strong> <ul class="decimal_heading"> <li>Routinely evaluate signs and symptoms</li> <li>Assess tonsil size</li> </ul> <p class="extra_spacing_top"><strong>Diagnostic test:</strong></p> <ul class="decimal_heading"> <li>Polysomnogram (sleep study)</li> </ul> </td> <td> <ul> <li>Perform polysomnogram in patients who have obesity and symptoms suggesting obstructive sleep apnea<sup>◊</sup></li> </ul> </td> </tr> <tr> <td>SCFE</td> <td>Unexplained limp or aching pain in hip, groin, thigh, or knee</td> <td> <ul> <li>Hip radiographs</li> </ul> </td> <td> <ul> <li>Use frog-leg positioning for radiograph</li> <li>Children with acute symptoms of SCFE should immediately stop all weightbearing activity (including walking) to prevent further displacement<sup>[3]</sup></li> </ul> </td> </tr> <tr class="highlight_lght_gray_text"> <td>Varus (Blount disease) or valgus deformity</td> <td>Varum (bow legs) or varus (knock knees) deformity on examination, with or without knee pain</td> <td> <ul> <li>Knee radiographs</li> </ul> </td> <td> </td> </tr> <tr> <td>Polycystic ovary syndrome</td> <td>Menstrual irregularity, excessive acne, hirsutism</td> <td><strong>Initial tests:</strong> <ul class="decimal_heading"> <li>Total testosterone (or free testosterone)</li> <li>Beta-hCG, TSH, prolactin, DHEAS, 17-hydroxyprogesterone (early morning)</li> </ul> </td> <td> <ul> <li>Initial tests are to confirm whether hyperandrogenemia is present and exclude other causes of hyperandrogenemia and/or abnormal menses</li> <li>If laboratory testing is abnormal, additional workup is indicated</li> </ul> </td> </tr> <tr class="highlight_lght_gray_text"> <td>Impaired kidney function</td> <td>Asymptomatic</td> <td><strong>Screening:</strong> <ul class="decimal_heading"> <li>BUN, creatinine</li> <li>Urine for UACR</li> </ul> <p class="extra_spacing_top"><strong>Indications:</strong></p> <ul class="decimal_heading"> <li>Perform in adolescents with severe obesity, hypertension, or type 2 diabetes<sup>§</sup></li> </ul> </td> <td> <ul> <li>Perform in adolescents with severe obesity, hypertension, or type 2 diabetes<sup>§</sup></li> <li>UACR &gt;30 mg/g is abnormal</li> </ul> </td> </tr> <tr> <td>Precocious puberty</td> <td>Appearance of secondary sexual characteristics &lt;8 years (females) or &lt;9 years (males)</td> <td><strong>Initial tests:</strong> <ul class="decimal_heading"> <li>LH, FSH, testosterone or estradiol</li> </ul> </td> <td> <ul> <li>Physical examination is often sufficient to evaluate</li> <li>Laboratory testing depends on child's age and pubertal progression</li> <li>Central nervous system imaging may be indicated in selected children with central precocious puberty</li> </ul> </td> </tr> <tr class="highlight_lght_gray_text"> <td>Pseudotumor cerebri</td> <td>Headaches (especially morning), nausea/vomiting, blurred or decreased vision</td> <td><strong>Initial test:</strong> <ul class="decimal_heading"> <li>Funduscopic examination and/or refer to pediatric neurologist or ophthalmologist</li> </ul> </td> <td> <ul> <li>Increased intracranial pressure suggested by papilledema and confirmed by lumbar puncture</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">This table summarizes the evaluation for obesity-related comorbidities in children. For details on the evaluation, refer to UpToDate content on the health consequences of obesity in children and adolescents and relevant topic reviews.</div><div class="graphic_footnotes"><p>ABPM: ambulatory blood pressure monitoring; ALT: alanine aminotransferase; AST: aspartate aminotransferase; BP: blood pressure; BUN: blood urea nitrogen; CBC: complete blood count; CVD: cardiovascular disease; DHEAS: dehydroepiandrosterone sulfate; FSH: follicle-stimulating hormone; GGTP: gamma-glutamyl transpeptidase; HbA1c: glycated hemoglobin; hCG: human chorionic gonadotropin; LH: luteinizing hormone; MASH: metabolic dysfunction-associated steatohepatitis; MASLD: metabolic dysfunction-associated steatotic liver disease; RUQ: right upper quadrant; SCFE: slipped capital femoral epiphysis; TSH: thyroid-stimulating hormone; UACR: urine albumin-to-creatinine ratio; ULN: upper limit of normal.</p>
<p>* For interpretation of serum ALT, use the ULN of 22 units/L for females and 26 units/L for males, as determined from healthy lean children in the National Health and Nutrition Examination Survey<sup>[4]</sup>. Note that these values are substantially lower than the ULNs reported in most pediatric hospital laboratories.</p>
<p>¶ Screening laboratory tests for suspected MASLD include a CBC with platelets, HbA1c, and lipid panel.</p>
<p>Δ Risk factors for type 2 diabetes include: family history of type 2 diabetes, high-risk race/ethnicity (Native American, African American, Latino, Asian American, Pacific Islander), signs of insulin resistance (eg, acanthosis nigricans), or conditions associated with diabetes (hypertension, dyslipidemia, polycystic ovary syndrome).</p>
<p>◊ Symptoms suggesting obstructive sleep apnea include persistent snoring (most nights, most sleeping positions), observed gasping or apneas, nocturnal enuresis, and morning headaches.</p>
§ Screening for impaired kidney function is recommended for patients with type 2 diabetes<sup>[5]</sup>. UpToDate authors also suggest this screening for patients with other risk factors for developing chronic kidney disease, including severe obesity and hypertension.</div><div class="graphic_reference">References:
<ol>
<li>Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: Summary report. Pediatrics 2011; 128:S213.</li>
<li>de Ferranti SD, Steinberger J, Ameduri R, et al. Cardiovascular Risk Reduction in High-Risk Pediatric Patients: A Scientific Statement From the American Heart Association. Circulation 2019; 139:e603.</li>
<li>Hampl SE, Hassink SG, Skinner AC, et al. Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity. Pediatrics 2023; 151:e2022060640.</li>
<li>Vos MB, Abrams SH, Barlow SE, et al. NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr 2017; 64:319.</li>
<li>ElSayed NA, Aleppo G, Aroda VR, et al. 14. Children and Adolescents: Standards of Care in Diabetes-2023. Diabetes Care 2023; 46:S230.</li>
</ol></div><div id="graphicVersion">Graphic 65547 Version 31.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
